logologo
QuantliQuantli

Cibus Inc

CBUS

NASDAQ

Biotechnology

$1.77

USD

-0.13 (-6.84%)

At close: Aug 14, 2026, 4:00 PM EDT

Market Cap $148.47M

Volume 331.9K

Price (USD)
Price (USD)

About Cibus Inc

Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California and currently employs 118 full-time employees. The company went IPO on 2017-07-20. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). The company is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. The company has a pipeline of five productivity traits. The company has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.

CEO

Dr. Peter Beetham

HQ

San Diego, CALIFORNIA, US

Founded

2017

Employees

118

Quantli Score

8.4

Outperform

Fin. Health

8.1

Profitability

7.6

Growth

9.0

Cash-Flow Q.

8.8

Key Metrics

6 metrics our research team weighs before forming a view on CBUS.

Based on Quantli research · SEC filings · as of Q1 2026

METRIC

VALUE

CHANGE

TREND (3Y)

Revenue Growth (TTM)

-9.8%

-114.6 pp

Gross Margin (TTM)

100.0%

0.0 pp

Operating Margin (TTM)

-1588.4%

+4337.0 pp

Net Margin (TTM)

-2427.2%

+3995.3 pp

ROE (TTM)

-293.2%

+119.4 pp

Free Cash Flow (TTM)

$-50.65M

Financial Snapshot

Full Financials

Revenue

$4.29M

-9.8%

YoY

Gross Margin

100%

TTM

0.0%

YoY

Net Income

$-104.03M

+65.9%

YoY

Operating Cash Flow

$-50.25M

+10.9%

YoY

Key Statistics

Open

$1.73

Previous Close

$1.90

Day Range

$1.53 - $1.79

52 Week Range

$1.09 - $4.19

Volume

331.9K

Average Volume (10 Days)

150.0K

Dividend Yield

Valuation Measurement

Market Cap

$148.47M

P/E Ratio (TTM)

P/S Ratio (TTM)

34.64

Price / Book

4.18

Financial Highlights

Profit Margin

-2427.2%

Return on Assets

-32.1%

Return on Equity

-293.2%

Revenue (TTM)

$4.29M

Net Income (TTM)

$-104.03M

Diluted EPS (TTM)

-$1.97

Total Cash (MRQ)

$30.32M

Levered FCF (TTM)

$-50.65M

Turn research into action

Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.

Position Strategy

Ride market cycles. Patient hold.

Best for:

Patient investors

Swing Strategy

Buy support, sell on recovery.

Best for:

Risk-tolerant

Trend Following

Enter on trend. Cut losses fast.

Best for:

Active traders

Go deeper on CBUS

Similar Stocks

CUE

Cue Biopharma Inc

$34.20

+10.0%

INDP

Indaptus Therapeutics Inc

$1.07

+0.9%

VTVT

vTv Therapeutics Inc

$30.12

-2.4%

EQ

Equillium Inc

$2.36

+17.4%

OTLK

Outlook Therapeutics Inc

$0.7600

-14.9%

GNLX

Genelux Corp

$2.74

+4.2%

IMDX

Insight Molecular Diagnostics Inc

$4.32

+16.4%

BDTX

Black Diamond Therapeutics Inc

$2.02

0.0%

Earnings Calendar

Next Earnings

Estimated Q3 Release

Nov 11

Est. EPS

Adjusted consensus estimate

-$0.24